Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 4/20 | 0.55 |
| ▸ | PRCP | P42785 | 4/20 | 0.54 |
| ▸ | DRD2 | P14416 | 2/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.54 |
| ▸ | DRD4 | P21917 | 1/20 | 0.53 |
| ▸ | DRD3 | P35462 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.50 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13588716 | 0.85 | SIGMAR1 (0.66) | SLC18A3PRCPDRD2SIGMAR1HRH3 | |
| SCHEMBL15549867 | 0.83 | SLC18A3 (0.62) | SLC18A3PRCPDRD2SIGMAR1DRD4 | |
| SCHEMBL7202138 | 0.82 | SLC18A3 (0.62) | SLC18A3DRD2SIGMAR1DRD4DRD3 | |
| SCHEMBL23816922 | 0.81 | SLC18A3 (0.60) | SLC18A3DRD2SIGMAR1DRD4DRD3 | |
| SCHEMBL4178029 | 0.80 | SLC18A3 (0.58) | SLC18A3DRD2SIGMAR1DRD4DRD3 | |
| SCHEMBL4178026 | 0.80 | SLC18A3 (0.58) | SLC18A3DRD2SIGMAR1DRD4DRD3 | |
| SCHEMBL26238905 | 0.79 | PRCP (0.58) | SLC18A3PRCPDRD2DRD4DRD3 | |
| SCHEMBL14207950 | 0.79 | DRD2 (0.63) | SLC18A3PRCPDRD2SIGMAR1DRD4 | |
| SCHEMBL26986820 | 0.79 | SLC18A3 (0.58) | SLC18A3PRCPDRD2SIGMAR1DRD4 | |
| SCHEMBL19703077 | 0.78 | ADAMTS5 (0.57) | PRCPSIGMAR1HRH3KCNH2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973041-B2 | Antiarthritic agents; psoriasis; anticancer agents;antiallergens; metalloprotease inhibitors. | INCYTE CORPORATION (US) | 2011-07-05 | — | — | US | disclosed |
| US-7491724-B2 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | INCYTE CORPORATION (US) | 2009-02-17 | — | — | US | disclosed |
| US-20080167288-A1 | Substituted cyclic hydroxamates as lnhibitors of matrix metalloproteinases | LNCYTE CORPORATION (US) | 2008-07-10 | — | — | US | disclosed |
| US-20050113344-A1 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | INCYTE CORPORATION | 2005-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167288-A1 | Substituted cyclic hydroxamates as lnhibitors of matrix metalloproteinases | MMP25, MMP9, MMP24 | SLC18A3 4001/4885PRCP 311/4885DRD2 3775/4885 |
| US-20050113344-A1 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | MMP25, MMP2, MMP14 | SLC18A3 3509/4885PRCP 368/4885DRD2 3405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.